Clinical drug testing

Jewish physicians from treating patients in hospitals or medical facilities that received government support. The Nazi government next banned publication of the Arzneiverorinungen. A central health ministry now declared which medicines could be prescribed by physicians and reimbursed by insurers. In response to these measures, the Drug Commission moved back under the control of the Society for Internal Medicine and discontinued its independent laboratory and clinical drug tests. 

Young, D.S. Thomas, D.W. Friedman, R.B..and Pestaner, L.C. "Effects of Drugs on Clinical Laboratory Tests". Clin. 

With an approved IND, the drug company can place me in humans at lower doses, mainly to observe any overt symptoms of toxicity and to evaluate my PK characteristics, and the study may use 10 to 20 healthy subjects. These data are then resubmitted to FDA (Phase 1). After my Phase I is completed, drug testing begins for my clinical efficacy, with trials at different doses and given to different populations under strict supervision. A successful study may require a few thousand patients and the involvement of several study centers across the country (or perhaps across the world) to collect extensive data. It is not unusual to have 100,000 patients take me before the data are submitted to the FDA for drug approval — the so-called marketing approval. 

C5. Caraway, W. T., and Kammeyer, C. W., Chemical interference by drugs and other substances with clinical laboratory test procedures. Clin. Chim. Acta 41, 345-434 (1972). 

Clinical trials— Tests of drugs on human subjects. 

The clinical drug development process required by the US FDA, arguably the most stringent in the world, starts with the investigational new drug (IND) application prior to human testing. It reveals information about all known compounds to be used and includes the description of the clinical research plan for the product as well as the protocol for phase I studies. Preclinical study results also need to be revealed. 

Prevalence rates in populations of injectors are often over 50%, and testing should be available in all clinical drug services... 

---